184例单纯疱疹病毒性脑炎患者中与阿昔洛韦给药延迟相关的因素。
Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis.
作者信息
Poissy J, Wolff M, Dewilde A, Rozenberg F, Raschilas F, Blas M, Georges H, Chaffaut C, Yazdanpanah Y
机构信息
Service Universitaire des Maladies Infectieuses et du Voyageur, Tourcoing, France.
出版信息
Clin Microbiol Infect. 2009 Jun;15(6):560-4. doi: 10.1111/j.1469-0691.2009.02735.x. Epub 2009 Apr 21.
The main predictor of outcomes in herpes simplex virus (HSV) encephalitis (HSE) is the delay between hospital admission and initiation of acyclovir. In this study, factors associated with late initiation of acyclovir were identified. The study included adults from northern France whose cerebrospinal fluid (CSF) was positive for HSV by PCR. Late initiation of acyclovir was defined as a delay of >1 day from hospital admission. In total, 184 patients were retrospectively enrolled from January 1991 to December 2002. The median age was 60 years (range: 17-91), and 102 (55.4%) were male. Acyclovir was initiated >1 day after hospital admission in 68 patients (37.0%). According to multivariate analysis, independent risk factors for late initiation of acyclovir were severe underlying disease (Knaus score >or=C) (OR 4.1; 95% CI 1.5-11.7); alcohol abuse (OR 3.4; 95% CI 1.3-8.9); and a delay of >1 day from admission to first brain imaging (OR 8.4; 95% CI 3.9-18.0). In addition, univariate analysis suggested an association between a finding of <10 leukocytes/mm(3) in CSF at admission (OR 2.5; 95% CI 0.7-5.8). These characteristics were found in 26 (14.1%), 23 (12.5%), 66 (35.9%) and 27 (14.7%) patients, respectively. One risk factor was identified in 109 (59.2%) patients, two in 29 (15.8%), and three in six (3.3%). Patients with HSE often present with severe underlying disease, chronic alcohol abuse, or atypical CSF findings, and such factors should not be allowed to delay diagnosis and administration of acyclovir.
单纯疱疹病毒性脑炎(HSE)预后的主要预测因素是入院与开始使用阿昔洛韦之间的延迟时间。在本研究中,确定了与阿昔洛韦延迟使用相关的因素。该研究纳入了法国北部脑脊液(CSF)经聚合酶链反应(PCR)检测HSV呈阳性的成年人。阿昔洛韦延迟使用定义为入院后延迟>1天。1991年1月至2002年12月共回顾性纳入184例患者。中位年龄为60岁(范围:17 - 91岁),男性102例(55.4%)。68例患者(37.0%)在入院>1天后开始使用阿昔洛韦。多因素分析显示,阿昔洛韦延迟使用的独立危险因素为严重基础疾病(克瑙斯评分≥C)(比值比[OR] 4.1;95%置信区间[CI] 1.5 - 11.7);酒精滥用(OR 3.4;95% CI 1.3 - 8.9);以及入院至首次脑部影像学检查延迟>1天(OR 8.4;95% CI 3.9 - 18.0)。此外,单因素分析提示入院时脑脊液白细胞计数<10/立方毫米与延迟使用阿昔洛韦有关(OR 2.5;95% CI 0.7 - 5.8)。分别有26例(14.1%)、23例(12.5%)、66例(35.9%)和27例(14.7%)患者存在这些特征。109例(59.2%)患者存在1个危险因素,29例(15.8%)存在2个危险因素,6例(3.3%)存在3个危险因素。HSE患者常伴有严重基础疾病、慢性酒精滥用或脑脊液检查结果不典型,不应让这些因素延误阿昔洛韦的诊断和使用。